Explanipedia

Efficacy of Contractility Modulation Therapy in Patients with Transthyretin Amyloid Cardiomyopathy, Mildly Reduced to Reduced EF and NYHA III and IV: A Multicentric, Prospective Pilot Study for AMY-CCM Registry Open

Procolo Marchese, Francesca Gennaro, Giovanni Mazzotta, Pierfrancesco Grossi, L Cocchiara , et al. · 2025

Background: Transthyretin cardiac amyloidosis (ATTR-CM) is an infiltrative cardiomyopathy that frequently progresses to symptomatic heart failure (HF), often with mildly reduced or reduced ejection fraction (EF). Standard therapies are lim…

Comparative Effects of Pulsed Field and Radiofrequency Ablation on Blood Cell Parameters During Pulmonary Vein Isolation Open

Lucio Addeo, Federica Feo, Mario Vaccariello, Alfonso Varriale, Benedetta Brescia , et al. · 2025

Background: Pulsed field ablation (PFA) is a novel non-thermal modality for pulmonary vein isolation (PVI) in atrial fibrillation (AF), offering myocardial selectivity through irreversible electroporation while sparing surrounding structur…

Not Afraid to Go Beyond Open

L Cocchiara, Benedetta Brescia, Stefano Nardi, A Salucci, Lucio Addeo , et al. · 2025

Time-dependent survival effectiveness of Sacubitril/Valsartan and Gliflozins in heart failure with reduced ejection fraction after cardiac resynchronization therapy Open

Paolo Visconti, Valerio Pergola, A Salucci, Danilo Faccenda, Giuseppe Ammirati , et al. · 2025

Time-dependent Survival Effectiveness of Sacubitril/Valsartan and Gliflozins in Cardiac Resynchronization Therapy Recipients Aims Robust evidence validating the long-term efficacy of Sacubitril/valsartan (ARNi), gliflozins (SGLT2i), and ca…

Prophylactic colchicine to reduce VOM ethanol infusion related Pericarditis Open

Procolo Marchese, L Cocchiara, Benedetta Brescia, Francesca Gennaro, G Mazzotta , et al. · 2025

Background/Introduction Pulmonary vein isolation (PVI) is an established treatment for atrial fibrillation (AF) [1], but for persistent AF PVI appears to be suboptimal and any kind of additional lesion has been proven to not enhance the ef…

A novel device to reduce the incidence of pocket hematoma Open

A Salucci, Lucio Addeo, Danilo Faccenda, Paolo Visconti, Valerio Pergola , et al. · 2025

Aims The incidence of pocket hematoma following cardiac device implantation varies widely, ranging from 0.2% to 16%. Pocket hematomas are clinically significant, as they are associated with a ninefold increased risk of infection. Preventin…

Tauropace reduces infections in patients with heart failure and reduced ejection fraction after cardiac electronic implantable device implantation Open

Danilo Faccenda, Valerio Pergola, A Salucci, Giuseppe Ammirati, Paolo Visconti , et al. · 2025

Background Infections associated with implantable cardiac electronic devices (CIEDs) pose a significant health risk and their incidence is currently increasing, thus the importance of novel prophylactic interventions has recently been emph…

Vein of Marshall ethanol infusion performed in single day discharge. Is it safe and feasible? Open

Pietro Marchese, L Cocchiara, Benedetta Brescia, Alessandro Rossi, F Gennaro , et al. · 2025

Background/Introduction Pulmonary vein isolation (PVI) is an established treatment for atrial fibrillation (AF) [1], but for persistent AF PVI appears to be suboptimal and any kind of additional lesion has been proven to not enhance the ef…

CIED replacement optimization: feasibility, safety and acceptability of day surgery setting for CIED replacement Open

L Cocchiara, Benedetta Brescia, G Comparone, Rosalba Mauriello, A Salucci , et al. · 2025

Introduction Cardiac implantable electronic device (CIED) replacement, mainly due to battery depletion[1], has become a pivotal aspect of activity in leading implant centers [2]. The complication rate significantly exceeds that of initial …

Physician workload related to ILR false alarms in the era of telemedicine Open

L Cocchiara, Benedetta Brescia, Alessandra Volpe, Danilo Faccenda, A Salucci , et al. · 2025

Introduction Implantable loop recorders (ILR) are an effective tool for the management of different clinical settings, and they have been used widely over past years. In patients with ILR, remote monitoring is now-days a must according to …

Transseptal puncture device integrated with 3D mapping visualizable streerable sheet: a feasibility study Open

Procolo Marchese, Francesca Gennaro, G Mazzotta, L Cocchiara, Benedetta Brescia , et al. · 2025

Background A novel transseptal crossing device combines the vessel dilator and transseptal needle into a single component. The needle lumen accepts a 0.32 inch guidewire. Inside the transseptal crossing device, the needle is affixed to a s…

Cardioneuroablation: the known and the unknown Open

A Marrese, Riccardo Persico, Emanuele Parlato, Danilo Faccenda, A Salucci , et al. · 2024

Cardioneuroablation (CNA) is a novel interventional procedure for the treatment of recurrent vasovagal syncope (VVS) and advanced atrioventricular block secondary to hyperactivation of vagal tone in young patients. By damaging the cardiac …

Device programming and SMART pass algorithm activation in subcutaneous implantable defibrillator patients: data from a remote monitoring database Open

Saverio Iacopino, Ezio Santobuono, L Cocchiara, Massimo Giammaria, Carlo Lavalle , et al. · 2024

Background In subcutaneous implantable cardioverter-defibrillator (S-ICD) recipients, a previous study demonstrated very low rates of delivered shocks and inappropriate shocks on programming a conditional zone between 200 and 250 bpm and a…

A time-dependent analysis of sacubitril/valsartan and gliflozins benefits in patients receiving cardiac resynchronization therapy Open

Danilo Faccenda, Valerio Pergola, A Salucci, A Marrese, G Comparone , et al. · 2024

Background While sacubitril/valsartan (ARNi), gliflozins (or SGLT2i) and cardiac resynchronization therapy (CRT) are firmly recognized as cornerstones of therapy for heart failure with reduced ejection fraction (HFrEF), robust evidence val…

Impact of taurolidine use during cardiac electronic implantable device implantation in heart failure patients Open

A Salucci, Valerio Pergola, Danilo Faccenda, L Cocchiara, A Marrese , et al. · 2024

Background Cardiac Implantable Electronic Device (CIED) infections represent a critical health threat with potentially fatal consequences. The TauroPace™ is an innovative solution that contains taurolidine specifically formulated to eradic…

Outcomes of ischemic stroke in patients with atrial fibrillation Open

A Marrese, Mario Meola, Celeste Fonderico, A Salucci, G Comparone , et al. · 2023

Funding Acknowledgements Type of funding sources: None. Background Patients with atrial fibrillation (AF) have higher risk of ischemic stroke. Purpose We investigated whether AF patients experiencing an ischemic stroke have worse outcomes.…

Response to cardiac resynchronization therapy and treatment with ARNi and iSGLT2 Open

Celeste Fonderico, Danilo Faccenda, Valerio Pergola, A Marrese, G Comparone , et al. · 2023

Funding Acknowledgements Type of funding sources: None. Background Heart failure with reduced ejection fraction (HFrEF) is associated in about one third of patients with abnormal conduction of the cardiac electrical impulse, resulting in a…

The Role of Sacubitril/Valsartan and Gliflozins in Heart Failure with Reduced Ejection Fraction after Cardiac Resynchronization Therapy Open

Celeste Fonderico, Valerio Pergola, Daniele Faccenda, G Comparone, A Marrese , et al. · 2023

BACKGROUND The angiotensin receptor-neprilysin inhibitor (ARNi) and the sodium- glucose co-transporter 2 inhibitors (SGLT2i) have improved the outcome of patients with heart failure and reduced ejection fraction (HFrEF). However, data char…

L Cocchiara YOU? Author Swipe